An AI-driven drug discovery platform that integrates scientific agents, biological foundation models, molecular simulations, and public biomedical databases to evaluate existing drugs and discover novel therapeutic candidates.
The platform operates through two complementary tracks: Known Drug Evaluation, which predicts drug suitability and biological responses using patient-specific genomic and cellular data or reference datasets, and De Novo Drug Discovery, which identifies disease-specific molecular targets, generates and optimizes candidate compounds, and evaluates their predicted binding, efficacy, and toxicity.
By combining cross-species evaluation across animal and human biological models with interactive 3D visualization, the system iteratively refines therapeutic hypotheses and proposes evidence-based wet-lab experiments for validation.